Home › Ulcerative Colitis › Louisiana
Ulcerative Colitis clinical trials in Louisiana
15 studies for Ulcerative Colitis are looking for participants at sites in Louisiana.
Cities in Louisiana
- Metairie8 studies
- New Orleans6 studies
- Lafayette5 studies
- Baton Rouge4 studies
- Monroe3 studies
- Shreveport3 studies
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Group and Endocenter: Mandeville, la /ID# 284186, Mandeville
- Metropolitan Gastroenterology Associates - Metairie /ID# 283922, Metairie
- Willis-Knighton Medical Center /ID# 280572, Shreveport
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Baton Rouge General Medical Center - Bluebonnet Campus, Baton Rouge
- Combined Gastro LLC, Lafayette
- GI Alliance, Metairie
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Clinical Trials Management, LLC, Metairie
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT06598943A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 035, Marrero
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-008, Baton Rouge
- Site US-011, Mandeville
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07845487A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
- Tulane University School of Medicine-Gastroenterology and Hepatology ( Site 1073), New Orleans
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 28, 2026 · NCT07463183A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- Delta Research Partners, LLC, West Monroe
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT07196748Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Care Access - New Iberia, New Iberia
- Louisiana Research Center, Shreveport
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937086LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- GI Alliance - Gastro Group and Endocenter - Mandeville, Mandeville
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07415044A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- GI Alliance, Metairie
- Tulane University, New Orleans
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Sep 21, 2026 · NCT06095128A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- GI Alliance - Baton Rouge - Site Number: 8400129, Baton Rouge
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville - Site Number: 8400128, Mandeville
- Delta Research Partners - Site Number: 8400087, Monroe
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 15, 2026 · NCT07185009A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- Gastroenterology Clinic of Acadiana, Lafayette
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07577856An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- GI Alliance - Baton Rouge - Site Number: 8400129, Baton Rouge
- Tandem Intermediate, LLC - Houma -Site Number: 8400034, Houma
- GastroGroup - Site Number: 8400128, Mandeville
- and 4 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Aug 20, 2026 · NCT07184996A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Lafayette
- Mirador Therapeutics Selected Site, Marrero
- Mirador Therapeutics Selected Site, Shreveport
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- Tulane University, New Orleans
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 8, 2025 · NCT06750731From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.